H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Precigen (PGEN – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $1.21.
According to TipRanks, Ramakanth is an analyst with an average return of -15.4% and a 29.08% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Ocugen, Electrocore, and Bicycle Therapeutics.
Precigen has an analyst consensus of Strong Buy, with a price target consensus of $8.77, representing a 624.79% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.90 and a one-year low of $0.81. Currently, Precigen has an average volume of 1.73M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More on PGEN:
- Precigen Reports First Quarter 2023 Financial Results and Business Updates
- PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Precigen’s UltraCAR-T platform shows antitumor eefficacy in preclinical data
- Precigen amends exclusive license agreement with Alaunos Therapeutics
- Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007
